- Storage{}{}{}
- Over dosage{}{}{}
- Side Effects{}{}{}
- Drug Interaction{}{}{}
- Lactation{}{}{}
- Pregnancy{}{}{}
- Precaution{}{}{}
- Contraindication{}{}{}
- Administration and Dosage{}{}{}
- Indication{}{}{}
- Mechanism of Action{}{}{}
Storage{}{}{}
<p style=\"text-align: left;\">Store below 30 <sup>o</sup>C. </p> <p style=\"text-align: left;\"> Protect from light and moisture. </p> <p style=\"text-align: left;\"> Keep out of rich of children.</p>
Over dosage{}{}{}
<p style=\"text-align: left;\">Contact a poison control center.</p>
Side Effects{}{}{}
<p style=\"text-align: left;\">Neutropenia- Agranulocytosis- Increased liver enzymes- discoloration of urine</p>
Drug Interaction{}{}{}
<ul> <li style=\"text-align: left;\">Medicinal products known to be associated with neutropenia or those that can cause agranulocytosis</li> <li style=\"text-align: left;\">The potential exists for interactions between deferiprone and trivalent cation-dependent medicinal products such as aluminium-based antacids.</li> <li style=\"text-align: left;\">The safety of concurrent use of deferiprone and vitamin C has not been formally studied.</li> <li style=\"text-align: left;\"> </li> </ul>
Lactation{}{}{}
<p style=\"text-align: left;\">It is not advised in nursing mother. If treatment is unavoidable, breast-feeding must be stopped.</p>
Pregnancy{}{}{}
<p style=\"text-align: left;\">FDA pregnancy category D</p>
Precaution{}{}{}
<ul> <li style=\"text-align: left;\">Renal or hepatic impairment and liver fibrosis</li> <li style=\"text-align: left;\">Symptom such fever, pharyngitis</li> </ul>
Contraindication{}{}{}
<ul> <li style=\"text-align: left;\">Hypersensitivity to the active substance or related family.</li> <li style=\"text-align: left;\">History of recurrent episodes of neutropenia.</li> <li style=\"text-align: left;\">History of agranulocytosis.</li> <li style=\"text-align: left;\">Pregnancy</li> <li style=\"text-align: left;\"> Breastfeeding</li> <li style=\"text-align: left;\">Patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis</li> </ul>
Administration and Dosage{}{}{}
<ul> <li style=\"text-align: left;\">Don’t chew or crush the tablets.</li> <li style=\"text-align: left;\">Posology: Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. A total daily dose above 100 mg/kg body weight is not recommended because of the potentially increased risk of adverse reactions</li> </ul>
Indication{}{}{}
<p style=\"text-align: left;\">It is licensed for the treatment of iron overload in patients with Thalassemia major in whom Deferoxamine is contra-indicated</p>
Mechanism of Action{}{}{}
<p style=\"text-align: left;\">It is oral iron chelator.</p>
Avideferone®
Deferiprone
Delayed Release Tablet
Reminder:
This medicine has been prescribed for your medical condition. Refrain from recommending it to others for similar medical conditions
References:
PDR 2020
Strength of this product:
500 mg
Reviews
There are no reviews yet.